Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as cell growth inhibition after 120 hrs by methylene blue staining based assay
Antitumor activity against human GIST430 cells xenografted in NOD/SCID mouse assessed as tumor regression at 30 mg/kg, po qd administered on day 1,2,5 to 9 and 12 to 16 measured after 30 days by digital caliper method relative to control
Antitumor activity against human GIST430 cells xenografted in NOD/SCID mouse assessed as decrease in tumor regrowth at 30 mg/kg, po qd administered on day 1,2,5 to 9 and 12 to 16 measured after 30 days by digital caliper method
Antitumor activity against human GIST430 cells xenografted in NOD/SCID mouse assessed as decrease in tumor regrowth at 80 mg/kg, po qd administered on day 1,2,5 to 9 and 12 to 16 measured after 30 days by digital caliper method
Antitumor activity against human GIST430 cells xenografted in NOD/SCID mouse assessed as tumor regression at 15 mg/kg, po qd administered on day 1,2,5 to 9 and 12 to 16 measured after 30 days by digital caliper method
Antitumor activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant xenografted in NOD-SCID mouse assessed as reduction in tumor size at 25, po administered for 2 weeks with 2 days rest after day 5 and measured thrice per week up to 14 days during compound dosing relative to control
Antitumor activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant xenografted in NOD-SCID mouse assessed as tumor growth inhibition at 25 mg/kg, po administered for 2 weeks with 2 days rest after day 5 and measured thrice per week up to 21 days during compound dosing
Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as reduction in cell viability by methylene blue staining based assay
Antitumor activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant xenografted in NOD-SCID mouse assessed as tumor regression at 40 mg/kg, po administered for 2 weeks with 2 days rest after day 5 and measured thrice per week up to 21 days during compound dosing
Antitumor activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant xenografted in NOD-SCID mouse assessed as tumor growth inhibition at 40 mg/kg, po administered for 2 weeks with 2 days rest after day 5 and measured thrice per week up to 21 days during compound dosing